Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (Nasdaq: COGT) generates frequent news flow as a biotechnology company developing precision therapies for genetically defined diseases. Its updates often center on the clinical and regulatory progress of bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V and other KIT exon 17 mutations associated with systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST).
News for COGT commonly includes clinical trial milestones from the pivotal SUMMIT, APEX and PEAK studies. SUMMIT evaluates bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM), APEX in Advanced Systemic Mastocytosis (AdvSM), and PEAK in imatinib-resistant or intolerant GIST in combination with sunitinib. Press releases have highlighted positive top-line results, detailed efficacy and safety data, and plans for New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.
Investors and followers of COGT can also expect regulatory and designation announcements, such as Breakthrough Therapy Designation for bezuclastinib in specific NonAdvSM populations, as well as updates on Expanded Access Programs for eligible GIST and SM patients. Financial and corporate news appears regularly, including equity and convertible note offerings, cash runway commentary, and participation in major healthcare investor conferences like the J.P. Morgan Healthcare Conference and the Jefferies Global Healthcare Conference.
In addition, Cogent issues news on its early-stage pipeline, including a selective and potent FGFR2/3 inhibitor in Phase 1/2 and discovery programs targeting ErbB2, PI3Kα, KRAS and JAK2. For readers tracking COGT, this news page provides an organized view of trial readouts, regulatory plans, financing events and scientific presentations that shape the company’s development trajectory. Bookmark this feed to monitor Cogent’s ongoing disclosures about its precision oncology and hematology programs.
Cogent Biosciences (Nasdaq: COGT) will participate in the 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 2, 2020, at 10:55 a.m. ET. CEO Andrew Robbins is scheduled for a virtual fireside chat. Investors can access a live audio webcast via the 'Events' tab on Cogent's investor relations website, with a replay available for 30 days post-event. Cogent focuses on precision therapies for genetically defined diseases, including its advanced clinical program, PLX9486, which targets the KIT D816V mutation.
Cogent Biosciences announced the final results of its Phase 1/2 trial of PLX9486 combined with sunitinib for advanced gastrointestinal stromal tumors (GIST) on Nov 18, 2020. The median progression-free survival (PFS) for treated patients was 12 months, indicating potential effectiveness. With encouraging outcomes documented in patients with imatinib-resistant GIST, Cogent plans to advance this combination into a Phase 3 trial in the second half of 2021. The study included 18 patients, with an overall response rate of 20% and a clinical benefit rate of 80%, showcasing a promising treatment avenue.
Cogent Biosciences, headquartered in Cambridge, MA, announced that CEO Andrew Robbins will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, 2020. The presentation will discuss Cogent’s focus on precision therapies for genetically defined diseases, including their lead program, PLX9486, aimed at inhibiting the KIT D816V mutation associated with systemic mastocytosis and gastrointestinal stromal tumors. A recording of the presentation will be available on their investor relations website.
Cogent Biosciences (COGT) reported third-quarter 2020 financial results, highlighting a net loss of $50 million, or $5.07 per share, compared to a loss of $11.9 million in Q3 2019. Collaboration revenue decreased to $0.3 million, down from $1.0 million year-over-year. R&D expenses were reduced to $5 million, while G&A expenses increased to $5.6 million. The company completed the acquisition of Kiq LLC and raised $104.4 million through a Series A preferred stock placement. Following a 1-for-4 reverse stock split on November 6, 2020, COGT's common stock began trading on a split-adjusted basis.
Cogent Biosciences (COGT) announced that CEO Andrew Robbins will present a corporate overview at the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The presentation will focus on Cogent's precision therapies for genetically defined diseases, including the advanced clinical program PLX9486, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, associated with systemic mastocytosis and gastrointestinal stromal tumors. A recording of the presentation will be available on the company's investor relations website.
Cogent Biosciences, Inc. (NASDAQ: COGT) announced the appointment of Andrew Robbins as President and CEO, succeeding Chuck Wilson who founded the company in 2014. Robbins brings over 20 years of experience in oncology and hematology, including his previous role as COO at Array Biopharma. The board approved an inducement award for Robbins comprising options to purchase 7,442,421 shares at the recent closing price. Cogent aims to advance its lead asset, PLX9486, in treating systemic mastocytosis and GIST.